Andere talen Egetis Therapeutics AB

Aandelen

EGTX

SE0003815604

Beurs gesloten - Nasdaq Stockholm Andere beurzen 18:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,67 ^SEK	-6,32%		-25,52%	-16,31%

20/06	Transcript : Egetis Therapeutics AB - Special Call
19/06	Egetis Therapeutics AB (publ) kondigt topresultaten aan van de Fase 2 Triac Trial II met Emcitate (tiratricol) voor MCT8-deficiëntie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency	19/06
Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	19/06
Egetis awarded Promising Innovative Medicine designation in the UK for Emcitate® (tiratricol) for treatment of MCT8 deficiency	03/06
Egetis Receives Promising Innovative Medicine Designation in the UK for Emcitate® for Treatment of MCt8 Deficiency	03/06
Bulletin from Egetis Therapeutics’ Annual General Meeting 2024	06/05
Egetis Therapeutics Q1 2024 - EU launch closing in	06/05
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)	24/04
Egetis Therapeutics' : 2023 Annual Report published	15/04
Egetis Therapeutics’ 2023 Annual Report published	15/04
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)	29/03
Egetis Therapeutics - Continued progress in Q4	23/02
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Egetis Therapeutics : – Corporate Presentation December 2023	27/12
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	22/12
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance	22/12
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today	19/12
Egetis’ Investor Day on December 19: Agenda and Registration Details	14/12
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA	13/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Egetis Therapeutics AB

Aandelen

EGTX

SE0003815604

Andere talen

Filters